Overview
- Kyrgios provided a urine sample in late June that a WADA‑accredited laboratory later confirmed contained benzoylecgonine, and the International Tennis Integrity Agency placed him under a mandatory provisional suspension on Aug. 4.
- Kyrgios publicly acknowledged the positive test on Aug. 19, called it “a huge mistake,” and framed the episode against recent injuries and mental strain.
- At the US Open, Stefanos Tsitsipas said he knew about the failed test before it was announced but did not explain how he learned of it, drawing attention to inside‑tour awareness and the rivals’ fraught history.
- The case now moves to an independent tribunal that can impose sanctions up to four years; penalties will depend on whether authorities judge the use to have been in‑competition or out‑of‑competition and on the circumstances of ingestion.
- Beyond the immediate disciplinary process, the episode risks further damage to Kyrgios’s comeback prospects given his recent injuries and limited play, and it raises questions about how news of anti‑doping matters travels within professional tennis.